Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

SOCS1 is an inducible negative regulator of interferon λ (IFN-λ)-induced gene expression in vivo.

Blumer T, Coto-Llerena M, Duong FHT, Heim MH.

J Biol Chem. 2017 Oct 27;292(43):17928-17938. doi: 10.1074/jbc.M117.788877. Epub 2017 Sep 12.

PMID:
28900038
2.

The Role of Interferons in Inflammation and Inflammasome Activation.

Kopitar-Jerala N.

Front Immunol. 2017 Jul 25;8:873. doi: 10.3389/fimmu.2017.00873. eCollection 2017. Review.

3.

STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling.

Arimoto KI, Löchte S, Stoner SA, Burkart C, Zhang Y, Miyauchi S, Wilmes S, Fan JB, Heinisch JJ, Li Z, Yan M, Pellegrini S, Colland F, Piehler J, Zhang DE.

Nat Struct Mol Biol. 2017 Mar;24(3):279-289. doi: 10.1038/nsmb.3378. Epub 2017 Feb 6.

4.

Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients.

Lee CM, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH, Yen YH.

BMC Gastroenterol. 2016 Jul 25;16(1):73. doi: 10.1186/s12876-016-0492-6.

5.

Signal transduction controls heterogeneous NF-κB dynamics and target gene expression through cytokine-specific refractory states.

Adamson A, Boddington C, Downton P, Rowe W, Bagnall J, Lam C, Maya-Mendoza A, Schmidt L, Harper CV, Spiller DG, Rand DA, Jackson DA, White MR, Paszek P.

Nat Commun. 2016 Jul 6;7:12057. doi: 10.1038/ncomms12057.

6.

Suppression of USP18 Potentiates the Anti-HBV Activity of Interferon Alpha in HepG2.2.15 Cells via JAK/STAT Signaling.

Li L, Lei QS, Zhang SJ, Kong LN, Qin B.

PLoS One. 2016 May 26;11(5):e0156496. doi: 10.1371/journal.pone.0156496. eCollection 2016. Erratum in: PLoS One. 2016;11(7):e0159019.

7.

Lipopolysaccharide and Tumor Necrosis Factor Alpha Inhibit Interferon Signaling in Hepatocytes by Increasing Ubiquitin-Like Protease 18 (USP18) Expression.

MacParland SA, Ma XZ, Chen L, Khattar R, Cherepanov V, Selzner M, Feld JJ, Selzner N, McGilvray ID.

J Virol. 2016 May 27;90(12):5549-5560. doi: 10.1128/JVI.02557-15. Print 2016 Jun 15.

8.

Antitumor and Antimetastatic Effect of Small Immunostimulatory RNA against B16 Melanoma in Mice.

Kabilova TO, Sen'kova AV, Nikolin VP, Popova NA, Zenkova MA, Vlassov VV, Chernolovskaya EL.

PLoS One. 2016 Mar 16;11(3):e0150751. doi: 10.1371/journal.pone.0150751. eCollection 2016.

9.

Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C.

Lu MY, Huang CI, Dai CY, Wang SC, Hsieh MY, Hsieh MH, Liang PC, Lin YH, Hou NJ, Yeh ML, Huang CF, Lin ZY, Chen SC, Huang JF, Chuang WL, Yu ML.

Sci Rep. 2016 Mar 11;6:22995. doi: 10.1038/srep22995.

11.

HMGB1 Is Involved in IFN-α Production and TRAIL Expression by HIV-1-Exposed Plasmacytoid Dendritic Cells: Impact of the Crosstalk with NK Cells.

Saïdi H, Bras M, Formaglio P, Melki MT, Charbit B, Herbeuval JP, Gougeon ML.

PLoS Pathog. 2016 Feb 12;12(2):e1005407. doi: 10.1371/journal.ppat.1005407. eCollection 2016 Feb.

12.

Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage.

Bhattacharya A, Hegazy AN, Deigendesch N, Kosack L, Cupovic J, Kandasamy RK, Hildebrandt A, Merkler D, Kühl AA, Vilagos B, Schliehe C, Panse I, Khamina K, Baazim H, Arnold I, Flatz L, Xu HC, Lang PA, Aderem A, Takaoka A, Superti-Furga G, Colinge J, Ludewig B, Löhning M, Bergthaler A.

Immunity. 2015 Nov 17;43(5):974-86. doi: 10.1016/j.immuni.2015.10.013.

13.

Immune and non-immune responses to hepatitis C virus infection.

Sun J, Rajsbaum R, Yi M.

World J Gastroenterol. 2015 Oct 14;21(38):10739-48. doi: 10.3748/wjg.v21.i38.10739. Review.

14.

Interferon Response in Hepatitis C Virus (HCV) Infection: Lessons from Cell Culture Systems of HCV Infection.

Sung PS, Shin EC, Yoon SK.

Int J Mol Sci. 2015 Oct 7;16(10):23683-94. doi: 10.3390/ijms161023683. Review.

15.

Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response.

Read SA, Tay ES, Shahidi M, O'Connor KS, Booth DR, George J, Douglas MW.

PLoS One. 2015 Aug 27;10(8):e0136227. doi: 10.1371/journal.pone.0136227. eCollection 2015.

16.

Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness.

Sung PS, Cheon H, Cho CH, Hong SH, Park DY, Seo HI, Park SH, Yoon SK, Stark GR, Shin EC.

Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10443-8. doi: 10.1073/pnas.1513341112. Epub 2015 Jul 27.

17.

IFN-λ: A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research.

Liu B, McGilvray I, Chen L.

Gastroenterol Res Pract. 2015;2015:796461. doi: 10.1155/2015/796461. Epub 2015 May 20. Review.

18.

USP18 Sensitivity of Peptide Transporters PEPT1 and PEPT2.

Warsi J, Hosseinzadeh Z, Elvira B, Pelzl L, Shumilina E, Zhang DE, Lang KS, Lang PA, Lang F.

PLoS One. 2015 Jun 5;10(6):e0129365. doi: 10.1371/journal.pone.0129365. eCollection 2015.

19.

The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections.

Egli A, Santer DM, O'Shea D, Tyrrell DL, Houghton M.

Emerg Microbes Infect. 2014 Jul;3(7):e51. doi: 10.1038/emi.2014.51. Epub 2014 Jul 16. Review.

20.

Hepatitis C Virus. Strategies to Evade Antiviral Responses.

Gokhale NS, Vazquez C, Horner SM.

Future Virol. 2014;9(12):1061-1075.

Supplemental Content

Support Center